Nature's Bounty: Plans to invest 240 million yuan to advance the research and development of dual-target CAR-T project.

Tian Shilai announced that the company plans to sign a "Cooperation Agreement" with Beijing Neurosurgical Institute and Beijing Rencheng Neuro-Oncology Biotechnology Engineering Research Center Co., Ltd., to jointly promote the research and industrialization of autologous CAR-T products targeting CD44 and CD133. The project has entered Phase I clinical trials, with the indication being recurrent glioblastoma. Tian Shilai, as the holder of the marketing authorization, will lead the research and commercialization, and is expected to invest 160 million yuan; Beijing Rencheng Biological is expected to invest 80 million yuan, and both parties will distribute sales profits according to the actual research investment ratio. The product developed in this cooperation is an autologous CAR-T product targeting CD44 and CD133. The company obtained clinical approval for this product in April 2025, with the approved indication being recurrent glioblastoma. It has already entered Phase I clinical trials. It can specifically recognize and bind to mutually exclusive high-expressing antigen targets in primary and recurrent glioblastomas, efficiently activate and prolong the lifespan of T cells, thus killing tumor cells.